baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cyclacel Pharmaceuticals Inc/ US23254L8019 /

2024-04-26 9:59:53 PM	Chg. -0.0900	Volume	Bid1:07:34 AM	Ask1:07:34 AM	High	Low
1.5100USD	-5.63%	181,642 Turnover: 189,168.5484	1.4900Bid Size: 800	1.5100Ask Size: 1,200	1.5600	1.4600

GlobeNewswire 04-01 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadra...

GlobeNewswire 03-19 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Bu...

GlobeNewswire 03-13 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 03-07 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented...

GlobeNewswire 03-06 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

GlobeNewswire 02-20 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

GlobeNewswire 01-30 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

GlobeNewswire 01-08 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire 01-02 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

GlobeNewswire 2023-12-22 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Ma...

GlobeNewswire 2023-12-18 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CD...

GlobeNewswire 2023-12-12 Cyclacel Pharmaceuticals Announces Reverse Stock Split

GlobeNewswire 2023-11-30 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

GlobeNewswire 2023-11-28 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Repor...

GlobeNewswire 2023-11-13 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire 2023-11-07 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

GlobeNewswire 2022-03-28 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-03-22 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-03-09 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire 2022-02-07 Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

GlobeNewswire 2021-12-23 Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

GlobeNewswire 2021-11-10 Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 2021-11-05 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With L...

GlobeNewswire 2021-10-29 Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

GlobeNewswire 2021-09-08 Cyclacel Pharmaceuticals Presenting at Three Conferences in September

Cyclacel Pharmaceuticals Inc/ US23254L8019 /

If you wish to receive reply to your feedback, please provide your email address.